[1] BHARGAVA A,MISHRA D,BANERJEE S,et al.Dendritic cell engineering for tumor immunotherapy:from biology to clinical translation[J].Immunotherapy,2012,4(7):703-718.
[2] TURTLE C J,RIDDELL S R.Artificial antigen-presenting cells for use in adoptive immunotherapy[J].Cancer J,2010,16(4):374-381.
[3] ZHANG L,WANG L,SHAHZAD K A,et al.Paracrine release of IL-2 and anti-CTLA-4 enhances the ability of artificial polymer antigen-presenting cells to expand antigen-specific T cells and inhibit tumor growth in a mouse model[J].Cancer Immunol Immunother,2017,66(9):1229-1241.
[4] STEENBLOCK E R,WRZESINSKI S H,FLAVELL R A,et al.Antigen presentation on artificial acellular Substrates:modular systems for flexible,adaptable immunotherapy[J].Expert Opin Biol Ther,2009,9(4):451-464.
[5] SHEN C,ZHANG J,XIA L,et al.Induction of tumor antigen-specific cytotoxic T cell responses in naïve mice by microspheres-based artificial antigen-presenting cell constructs[J].Cellular Immunology,2007,247(1):28-35.
[6] SHEN C,CHENG K,MIAO S,et al.Latex bead-based artificial antigen-presenting cells induce tumor-specific CTL responses in the native T-cell repertoires and inhibit tumor growth[J].Immunol Lett,2013,150(1-2):1-11.
[7] DURAI M,KRUEGER C,YE Z,et al.In vivo functional efficacy of tumorspecific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC)[J].Cancer Immunol Immunother,2009,58(2):209-220.
[8] LU X,JIANG X,LIU R,et al.In vivo anti-melanoma efficacy of allo-restricted CTLs specific for melanoma expanded by artificial antigen-presenting cells[J].Cancer Immunol Immunother,2009,58(4):629-638.
[9] CHIU Y,SCHNECK J P,OELKE M.HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL[J].J Vis Exp,2011,doi:10.3791/2801
[10] PERICA K,KOSMIDES A K,SCHNECK J P.Linking form to function:biophysical aspects of artificial antigen presenting cell design[J].Biochim Biophys Acta,2014,1853(4):781-790.
[11] BRUNS H,BESSELL C,VARELA J C,et al.CD47 enhances in vivo functionality of artificial antigen-presenting cells[J].Clin Cancer Res,2015,21(9):2075-2083.
[12] SINGH M,CHAKRAPANI A,O'HAGAN D.Nanoparticles and microparticles as vaccine-delivery systems[J].Expert Res Vaccines,2007,6(5):797-808.
[13] KOHANE D S.Microparticles and nanoparticles for drug delivery[J].Biotechnol Bioeng,2007,96(2):203-209.
[14] BALMERT S C,LITTLE S R.Biomimetic delivery with micro-and nanoparticles[J].Adv Mater,2012,24:3757-3778.
[15] GEEKIYANAGE H,GALANIS E.MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors[J].Mol Oncol,2016,10(9):1387-1403.
[16] DONAT U,ROTHER J,SCHAFER S,et al.Characterization of metastasis formation and virotherapy in the human C33A cervical cancer model[J].PLoS One,2014,9(6):e98533.
[17] KHOJA L,ATENAFU E G,YE Q,et al.Real-world efficacy,toxicity and clinical management of ipilimumab treatment in metastatic melanoma[J].Oncol Lett,2016,11(2):1581-1585. |